

We investigate, we move forward.

Impact report

2023

pasqual
maragall
foundation

barcelonaβeta
BRAIN RESEARCH CENTER

We
investigate,
**we move
forward.**

Impact report

2023

pasqual
maragall
foundation

barcelonaβeta
BRAIN RESEARCH CENTER

20

Edition

Pasqual Maragall Foundation
BarcelonaBeta Brain Research Center Foundation

Wellington, 30
08005 Barcelona
933 160 990

info@fpmaragall.org
info@barcelonabeta.org

www.fpmaragall.org
www.barcelonabeta.org

Art direction

marcmontala.com

Publication date

June 2024

Total or partial reproduction of this publication, treatment in any form or by any means, electronic, mechanical, photocopying, recording, or other methods, or its loan, rent or any other form of cession of use of the copy is not allowed without prior written permission of the copyright holder.

23

→ Greetings	06
→ Alzheimer's today	08
→ Milestones of the year	09
→ In detail	15
→ Research	19
→ Support programmes	27
→ You make it possible	28

Greetings



Arcadi Navarro

Director of the Pasqual Maragall Foundation
and the BarcelonaBeta Brain Research Center

Let's investigate and move forward. This is what we have done during 2023. In the global panorama of Alzheimer's research, it has been a year marked by an important paradigm shift in the approach to the disease due to the approval in the United States of new treatments that are getting closer, but have not yet reached Europe. In this context, our work in research and visibility of Alzheimer's is more necessary than ever.

I share this report with the conviction that thanks to our entire social base, which at the time of writing these lines exceeds 75,000 people, companies, sponsors and patrons, we have contributed to the materialization of this paradigm shift and therefore, to be closer to a future without Alzheimer's.

It has been four years since I addressed you with this report and, year after year, it becomes more difficult for me to summarise in a few lines the great amount of work we do in research and in the social field. In research, in 2023 we have made important advances, such as **validating with artificial intelligence a new biomarker of brain aging or describing the genetic profiles of people at greater risk of developing the disease**, at the same time as we brought together for the first time more than **80 international experts to discuss biomarkers** for neurodegenerative diseases at our center, the BBRC.

All this, while we have presented the results of the report "Spain on the world map of scientific production in dementia and Alzheimer's" which places the country's research among the world leaders, and where Barcelona and Madrid stand out among the 10 most productive cities in dementia research in the world. This places Barcelona in a highly competitive position thanks to several centers of excellence, among which the BBRC is located, and opens the door to future alliances that will promote even more and better research in our country.

Likewise, in 2023 we awarded the first grants of the **Pasqual Maragall Researchers Programme**, the best-endowed private programme for research on Alzheimer's or neurodegenerative diseases associated with age, and of which we are already working on a second edition that will allow to develop more research in the state, beyond our center.

Regarding our work with families, we have continued with our programmes to support carers, both in-person and online. **We have organised more than 40, which have been attended by more than 300 people from all over Spain**, 100 more than in 2022.

Even more: in order to change the social consideration of the disease, **we have demanded in the Senate more public funding for research into Alzheimer's** and other dementias, as well as the priority of making it an issue in the political debate. And also, we have not stopped spreading the word with our **Brain Film Fest** which celebrated its sixth edition, with more than **50 talks throughout Spain**, and we have presented the second wave of the *Attitudes survey and Perceptions of the Spanish population about Alzheimer's*, a sample of more than 2,300 people, which we announced on **World Alzheimer's Day** and which shows that Alzheimer's remains one of the health conditions that most worries the Spanish population at a short distance from cancer.

I invite you to read this report where you will find a complete summary of our activity, developed thanks to all of you, the **75,000 members who are part of our social base**. Without you, this would not be possible.

Thank you all, and let's continue our work to achieve a future without Alzheimer's.

2023

Alzheimer's today

Alzheimer's disease is the main cause of **dementia**, responsible for **60% to 70% of cases**. It is estimated that in Spain there are more than **900,000 people suffering from Alzheimer's** and other dementias, a figure that will double in the next twenty years.



900 Thousand people¹
suffer from Alzheimer's and other dementias.



2 out of 3 people²
have or have had someone with Alzheimer's in their environment.



80% of people³
with Alzheimer's are cared for by family.

¹ Assessing the socioeconomic impact of Alzheimer's in Western Europe and Canada (2017)

² Actitudes y percepciones de la población española sobre el Alzheimer, Fundación Pasqual Maragall (2020)

³ Coduras A, Rabasa I, Frank A, Bermejo-Pareja F, Lopez-Pousa S, Lopez-Arrieta JM, et al. Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study. J Alzheimers Dis. 2010; 19(2):601-15. <https://pubmed.ncbi.nlm.nih.gov/20110605/>

Milestones of the year


01



We celebrate the sixth edition of the Brain Film Fest

The sixth edition of the festival, held between March 15 and March 19 at the CCCB, Barcelona, recognises the career of **filmmaker Isabel Coixet** with the **Brain Film Fest Special Prize** for the delicacy, precision and respect she has shown when treating trauma and post trauma in her filmography.

02



We establish new guidelines for innovative services with the aim of preventing Alzheimer's

The proposal, in which the BBRC collaborates together with 28 European institutions, includes the creation of **second-generation memory clinics**, called 'Brain Health Services', for a segment of the population without cognitive impairment, which wishes to preserve or improve its memory.

03



We care for those who care

More than **300 caregivers of relatives with Alzheimer's** have participated in the 40 support groups organised by the Foundation.

04



The Foundation obtained funding for its Beta-AARC study, thanks to the campaign 'The Biggest Lie About Alzheimer's Ever Told'

Thanks to the support of our community, the BBRC will conduct the Beta-AARC study to analyse a new cohort of **200 participants, aged 55 to 80, who are experiencing subjective memory or cognitive impairments**. This research project focuses on the factors influencing disease onset and the detection of biomarkers that can identify individuals at higher risk of developing Alzheimer's before the first symptoms appear.

05



We celebrate the 4th edition of the series of talks "Recorda" (Remember)

The series of talks, held virtually and with the **participation of more than 1,000 people**, addresses the **future of Alzheimer's drugs**, as well as the communication with a person living with / affected by the disease.

06



We demand from the Senate more public funding for Alzheimer's research

The president of the Pasqual Maragall Foundation claims the need to take Alzheimer's and dementia into account in the **current political debate to promote (appropriate) measures and solutions**.

07



We demonstrate the effectiveness of amyloid PET as a diagnostic tool

The European **AMYPAD** study, in which the BBRC participates, demonstrates the clinical utility of this test in the early stages of diagnosis. Thanks to this neuroimaging technique, **deposits of the beta amyloid protein associated with Alzheimer's can be detected and evaluated** in the brain.

08



We run for a future without Alzheimer's at the 43rd El Corte Inglés Race

More than **26,000 people** took part in the **43rd El Corte Inglés Race**, in Barcelona, in favor of a future without Alzheimer's. Thanks to the success of this edition, we were able to **raise more than 22,000 euros** for the social and scientific project of the Foundation and the BBRC.

09



We host the 6th Edition of the Workshop on biomarkers for neurodegenerative diseases at our headquarters

This crucial scientific event in the area of biomedical research welcomed more than **80 international experts in the field of biomarkers for neurodegenerative diseases**, with a special focus on Alzheimer's.

10



We use artificial intelligence to validate a new biomarker of brain aging

This discovery has allowed us to demonstrate, for the first time, that the **presence of pathological alterations in Alzheimer's disease is associated with accelerated brain aging**, even in cognitively healthy people.


11



We validate the use of cognitive stimulation computer games to assess the evolution of cognitive ability in people at high risk of Alzheimer's

The tool has been approved by 56 participants, who are part of the **PENSA study**. This study aims to analyse whether **we can slow cognitive decline in early stages prior to the onset of dementia** through the intervention of a healthy lifestyle (Mediterranean diet, physical activity and cognitive training).

12



We collaborate in the PROMINENT European project

From the BBRC, we contribute to the development and validation of a **digital platform** for precision medicine to improve the diagnosis and treatment of Alzheimer's disease.

The main objective is to **support doctors** in relation to the individualised decision in the evaluation of patients with signs of cognitive decline.

13



We publish a bibliometric study that determines that Spain is among the top 10 countries in the world in Alzheimer's research

Barcelona ranks seventh in the global ranking as the **most productive city in Alzheimer's research, with 540 publications**. It also stands out for having a **large number of active researchers**, ranking tenth.


14



On World Alzheimer's Day, we highlight the numbers to forget

Once again, we claim the need to erase this celebration from the calendar and make this day **#undiaperoblidar (A day to forget)**, this year through the **4Iz3Imer action: the numbers to forget**.

15



We participate in a study that demonstrates the correlation between cardiovascular disease and dementia

From the BBRC we offer new data in the study published in *The Lancet Healthy Longevity*, and show that **atherosclerosis** - the accumulation of fatty plaques in the arteries - and its associated risk factors, in addition to being the main causes of cardiovascular disease, are also involved in brain **alterations which are typical of Alzheimer's disease**.

16



We conclude that Alzheimer's remains one of the health conditions that most worries Spanish society

The second wave of the "Attitudes and perceptions of the Spanish population on Alzheimer's" survey, with the support of the Ministry of Social Rights and Agenda 2030, **analyses the opinion of the population on different aspects of the disease** and provides an analysis of perceptions, knowledge and attitudes towards Alzheimer's and its research.

17



We award 1.6 million euros to the winning projects of the first edition of the Pasqual Maragall Researchers Programme research grants

Thanks to this first call and through the selected projects, the **programme supports research of excellence** led by other centers in Spain, will further strengthen the Foundation's research activity and opens **new perspectives in the approach to Alzheimer's** and other neurodegenerative diseases related to aging.

18



We win the REGIOSTARS 2023 award to promote a more competitive and intelligent Europe

We collect the REGIOSTARS Awards 2023 in the category "**A competitive and intelligent Europe**" in the Pasqual Maragall Foundation building. These awards **reward excellence, inclusiveness and impact** on regional development from projects financed with European funds.

19



Second edition of the Diana Garrigosa Awards

As part of the 6th Annual Meeting of the Foundation, held at the Palau de la Música Catalana and with the attendance of **more than 1,300 people**, we present the second edition of the **Diana Garrigosa Awards** to two models of active professionals who are committed to the defense of values and social rights: Victòria Camps, philosopher, former senator of the General Courts and former councilor of the State Council, and Iñaki Gabilondo, renowned journalist.

20



We organise 50 informative talks all over Spain

Throughout 2023, we have carried out **different trainings, open days, conferences, congresses and annual meetings** throughout the territory, in order to raise awareness of Alzheimer's disease, as well as to **answer questions about this type of dementia** and everything around it.

21



We reveal the genetic profiles of people at higher risk of Alzheimer's

A BBRC team characterises the **genetic predisposition to Alzheimer's and other neurological disorders** in cognitively healthy people in the preclinical stages of the disease. These results will help to **shape future studies** in the field of neurodegeneration, to understand the relationships between genetics and other risk factors, and to improve personalised prevention and potential specific treatments for the disease.

22



We include the largest number of healthy participants in the Ahead clinical study statewide

This study, started in 2022, aims **to evaluate the effectiveness and safety of an investigational drug (lecanemab) directed against the beta-amyloid protein** to prevent cognitive impairment in people aged 55–80, with high risk of developing Alzheimer's. The selected participants take the tests established in the trial protocol at the BBRC, such as neuropsychological tests, resonances or lumbar punctures, among others.

23



Let's explain our task


17 institutional visits have been made to the headquarters of the Pasqual Maragall Foundation as part of the invitations to political representatives **to raise awareness of the reality of Alzheimer's disease and the importance of its research**, as well as the social and scientific research of the Foundation and the BBRC, based on the early detection and prevention of Alzheimer's disease. Among them, the visits of the mayor of Barcelona, Jaume Collboni or the president of the Congress of Deputies, Meritxell Batet, stand out.

In detail

Economic activity

Budget


21.2M EUR



61% Pasqual Maragall Foundation
12.9M EUR

39% BBRC Research Center
8.3M EUR

Investment in Research in the last 10 years



MORE THAN
60M EUR
TOTAL 2013-2023

12.2M EUR
2023

Total revenue	€ 21,090,752	
Patrons, partners and donors	€ 12,138,232	58%
Research projects	€ 8,131,779	39%
Income from services	€ 420,916	2%
Public advocacy and institutional relations, social area and outreach	€ 399,825	2%
Total expenses	€ 20,863,493	
✦ Research programmes	€ 12,283,513	59%
✦ Communication and awareness	€ 2,145,299	10%
✦ Public advocacy and institutional relations, social area and outreach	€ 989,462	5%
Investment in partner and donor network	€ 4,603,126	22%
Administration	€ 842,094	4%


*




In 2023, we allocated **74%** of our budget directly to our mission, with the remaining **22%** invested in **guaranteeing the future sustainability** of this same mission: **achieving a world free of Alzheimer's and other neurodegenerative diseases.**

People

212
Foundation
employees



61% Women
39% Men



Scientific research

50 Published
articles



Published in **Q1 journals** **96%**

Published in **D1 journals** **83%**

+30
Ongoing studies

13
Study protocols

14
Conferences attended

4
Clinical trials

1,249
Clinical sessions

+40
Posters presented

18,292
Samples processed

467
Cognition sessions

914
MRIs

609
Nursing sessions

2,325
Sessions

Support programmes for caregivers



Education

+2M	Visits to the blog "Let's talk about Alzheimer's"	50	Educational talks
20	New blog articles	2,780	Brain Film Fest attendees
3	New help guides	17	Institutional visits



Media and communications

29	87
Press releases sent	New items added to website
2,349	622,799,133
Appearances in the media	Total viewers
€ 14,920,589	
Advertising value equivalent	




Social media

1,463
Social media posts
13,756,959
Comments
115,607
Followers

Social support

Evolution of the number of members



13,936 New members

6,483 Donations



74,980 Members



13 Companies on the Board of Patrons



523 Solidarity initiatives



623 Unforgettable shops and pharmacies



36 Bequests

€ 41,000 Amount received through bequests

220 Individuals expressing interest in bequests




330,510 Telephone queries

336,960 Street interactions

Research

In 2023, through the BarcelonaBeta Brain Research Center, we have continued our commitment to research as the primary path towards a future without Alzheimer's disease. We do this by focusing on prevention and the study of cognitive functions resulting from both healthy and pathological ageing. This work is driven by four highly collaborative research groups working to better understand the biological processes of the disease from various perspectives, and four research platforms dedicated to enhancing data collection, data utilization, and the integration of cutting-edge technologies.

Research groups



Clinical Research Group and Risk Factors for Neurodegenerative Diseases

It is made up of experts in clinical, genetics, biomarkers and neuropsychology who are in charge of examining the correlates of the biological processes that precede the onset of dementia. Its goal is to establish prevention programmes to stop or delay the onset of cognitive decline and dementia in asymptomatic people at risk.




Neuroimaging Research Group

It is structured in a multidisciplinary team of experts in the acquisition, processing and analysis of complex neuroimaging data, and they focus on the study of brain images obtained with magnetic resonance imaging (MRI) and positron emission tomography (PET). These images reveal pathophysiological changes associated with Alzheimer's disease and healthy aging that can be informative for new prevention strategies. Neuroimaging data are analysed together with cognition, genetics, biomarkers, and other clinical, environmental, and lifestyle factors to detect their impact on the brain at the structural, functional, and molecular levels.



Biomarkers Research Group in Fluids and Translational Neurology

It is made up of researchers with diverse backgrounds (clinical neurology, biochemistry, proteomics, bioinformatics, biostatistics and neuropsychology), and focuses on better understanding the biological basis of Alzheimer's and other age-related neurodegenerative diseases, especially during the early stages. The group has a strong translational focus and conducts research to develop, identify and validate biomarkers to improve the diagnosis of neurodegenerative diseases, discover new therapeutic targets and investigate the molecular mechanisms underlying these types of diseases.



Genomics Research Group

It is organised in a multi-institutional and transdisciplinary environment, with experts in genetics, bioinformatics, biochemistry and cell biology who carry out research on the genomics of neurodegeneration and aging. Its research focuses on the causes of aging and age-related diseases, especially neurodegenerative diseases.

Research facilities



Neuroimaging Platform

It is responsible for supporting the execution of research projects involving the acquisition, management and processing of brain images using magnetic resonance imaging. Its interdisciplinary team is responsible for optimizing the MRI sequences, maintaining the equipment and ensuring the quality of the images.



Fluid Biomarkers Facility

It addresses the entire biomarker development workflow, from candidate biomarker identification to assay development and clinical validation, to ultimately achieving clinical implementation. The platform aims to achieve a better understanding of neurodegenerative diseases, and to provide biomarkers that are relevant for clinical purposes.



Data Center

It works to provide high-quality data management procedures in research projects, as well as the design of procedures to maintain data integrity while respecting Good Clinical Practices (GCP) and legal restrictions, and ensuring the integrity, traceability and the quality of data management and analysis. Its work is essential so that the research staff can analyse, hypothesise and draw the main conclusions of their studies.



Research Management Office

It is in charge of providing assistance to the research community of the Barcelonaβeta Brain Research Center (BBRC) in the search for and obtaining competitive funds, offering support throughout the life cycle of each funded project. Likewise, the Research Management Office carries out medical writing tasks related to the design, implementation and execution of clinical studies sponsored by the BBRC, and the review and submission of scientific publications, among others. It is also responsible for the management of the Alfa+ project and collaborates in the identification and selection of candidates for other Alfa substudies.

Main research studies



Alfa study

The Alfa study is a research platform to **characterise the pathophysiology of Alzheimer's disease in its preclinical phase and develop preventive treatments**. It was launched in 2013 with the support of "la Caixa" Foundation. It is one of the most complex initiatives and with the largest number of research participants in the world, made up of **2,743 people between the ages of 45 and 75**, most of whom are sons and daughters of people with Alzheimer's.

The Alfa study is a strategic infrastructure for **research on the prevention and detection of Alzheimer's risk factors**. A large part of the studies developed at the BBRC are nourished by the data it generates. The exhaustive characterization of the participants turns Alfa into a **valuable research structure for conducting prevention clinical trials**.

2,743

People between the ages of 45 and 75

HeBe

The aim of HeBe is to identify blood factors that have a rejuvenating or aging effect on the human brain.

The results will improve the diagnosis of Alzheimer's disease or other neurodegenerative diseases in their earliest stages. They will also be useful for detecting people more susceptible to developing these diseases, predicting their prognosis, monitoring their progression and the effectiveness of a possible treatment.

This project receives funding from the European Research Council (ERC) within the framework of the European Union's Horizon 2020 research and innovation programme (grant agreement no. 948677).



PROAD

The PROAD project aims to identify proteomic profiles in blood that can predict cognitive decline in cognitively healthy people with an increased risk of developing Alzheimer's.

With this study, in which plasma samples from the Alfa+ cohort will be analysed, the BBRC team hopes to be able to find new prognostic biomarkers in the preclinical phase of the disease.

NeuroCOVID

This study, funded by La Marató de TV3 Foundation and lasting three years, investigates the neurological effects of Covid-19 in people with different risks of developing Alzheimer's.

To this end, the researchers use mini-brains as an analytical and predictive model, customised organoids of human brains, from participants of the Alfa cohort, and subjected to different traumas, including SARS-Cov2 infection.

Beta-AARC

The project 'Beta-AARC: Cohort study for the identification of blood biomarkers in the population with subjective cognitive decline', underway from 2021, deepens the knowledge of the factors that influence the onset of Alzheimer's disease and the detection of biomarkers to identify people at increased risk of developing the disease before the first symptoms appear.

It is a cohort study that will include approximately 200 people aged between 55 and 80 who experience a subjective deterioration of memory or other cognitive abilities, such as attention, planning ability and orientation.

The Beta-AARC study is supported by ACS Foundation, Condis, EDM, La Sirena and the Ramón Areces Foundation.



Alfa+

Alfa+ is a cohort, prospective and observational study that aims to describe the biological processes and identify factors that can predict the preclinical phase of Alzheimer's disease.

Thanks to the extensive characterization of 420 participants without cognitive impairment from the Alfa study, the Alfa+ analyses the association between biological, structural, functional and neurocognitive brain markers that characterise the preclinical phase of the disease and describe its natural history. It is supported by the Adey Foundation.



AlfaSleep

The aim of the AlfaSleep project is to characterise sleep patterns with subjective and objective measures in middle-aged adults without cognitive impairment and with an increased risk of developing Alzheimer's in the future, and relate them to biomarkers and state-of-the-art neuroimaging data.

Thanks to its multimodal approach and the study participant cohort, enriched by risk factors, the project will contribute to the understanding of the mechanisms underlying the association between sleep and cognitive impairment.

Thus, the project aims to develop non-invasive biomarkers and preventive strategies aimed at sleep. AlfaSleep has the participation of 200 people from the Alfa+ cohort.

PROSPECT-AD

Speech impairments are a feature of the early stages of Alzheimer's disease and, consequently, the analysis of speech performance is a promising new digital biomarker for the detection of the disease.

The aim of PROSPECT-AD is to validate speech biomarkers for the identification of individuals with early signs of Alzheimer's and monitor them longitudinally. In addition, digital biomarkers of language and speech open the door to screening methods for populations at greater risk of suffering the disease at very early stages, necessary for future clinical trials on Alzheimer's disease-modifying drugs. PROSPECT-AD collects data from participants from European cohorts, 100 of them from the BBRC Beta-AARC study.



Clinical trials



1,400
participants

AHEAD A3-45

The BBRC is one of the centers selected to participate in the AHEAD trial. The study plans to gather 1,400 participants from around the world to evaluate the efficacy and safety of a monoclonal antibody directed against the beta-amyloid protein, lecanemab, to prevent Alzheimer's disease in people aged 55 to 80 with high risk of developing it.

The selected participants will undergo the tests described in the trial protocol at the BBRC facilities, such as neuropsychological tests, or MRIs among others. The drug will also be administered to the people that meet all the requirements.

Elecsys Amyloid Plasma Panel

Elecsys Amyloid Plasma Panel (EAPP) is a multicenter, prospective and non-interventional study with the aim of demonstrating the clinical performance of the EAPP test, a test to facilitate the early diagnosis of Alzheimer's.

This tool would identify the likelihood of amyloid pathology in people with subjective memory complaints from a blood test, and determine whether they should undergo further evaluations and tests that could confirm the diagnosis. In this clinical trial will participate people aged between 55 and 80 with subjective memory complaints or mild cognitive impairment.

International consortia



PROMINENT

The BBRC is part of the **PROMINENT** consortium, a public-private collaboration, funded by the Innovative Health Initiative for a period of five years, which brings together experts in neurodegenerative diseases and clinical neuroscience, artificial intelligence, health economics and patient advocacy.

The project partners also include some of Europe's leading medical centers for the diagnosis and treatment of cognitive disorders.

SpeechDx

The Alzheimer's Drug Discovery Foundation (ADDF) SpeechDx longitudinal study is the first to create the largest repository of speech and voice data to help accelerate the detection, diagnosis and monitoring of Alzheimer's disease through these biomarkers.

The recorded voice samples from the study will be combined with clinical and biomarker data to develop algorithms for the creation of new speech biomarkers. The study will last three years and will collect data from 2,650 participants from five different centers, including the BBRC, which will contribute 400 people from the Alfa+ and Beta-AARC cohorts.

EU-FINGERS

The BBRC is partner and leader of one of the work packages of the "EUROFINGERS project: multimodal precision prevention toolbox for dementia in Alzheimer's disease".

This initiative aims to generate prevention tools for Alzheimer's disease and other dementias, and seeks to provide a common framework for multimodal studies on the prevention of dementia due to Alzheimer's disease.

In the context of this project, a BBRC study participant is part of the EU-FINGERS advisory committee to provide advice and recommendations to researchers and enrich the research with a diversity of voices and perspectives.

Scholarships and grants

Grants to support the scientific activity of research groups in Catalonia – Consolidated Research Group.

Lead Researcher (LR):

Dr. Karine Fauria

Funding: Agency for Management of University and Research Grants (AGAUR)

Reference: Project 2021 SGR 00913 financed by AGAUR of the Government of Catalonia

Grants to support the scientific activity of research groups in Catalonia – Emergent Research Group.

LR: Dr. Marc Suárez-Calvet

Funding: AGAUR

Reference: Project 2021 SGR 01137 funded by AGAUR of the Government of Catalonia

Improving Genetic prediction of Neurodegenerative processes using Brain Imaging Genetics (iGENE-BIG).

LR: Dr. Natàlia Vilor-Tejedor

Funding: State Research Agency (AEI) – Ministry of Science, Innovation and Universities

Reference: Project PID2022-143106OA-I00 funded by AEI and co-financed by the European Union (FEDER)

Postdoctoral contract, Juan de la Cierva programme.

LR: Dr. Federica Anastasi

Funding: AEI – Ministry of Science, Innovation and Universities

Reference: Project JDC2022-049347-I financed by AEI and co-financed by the European Union (NextGeneration EU/PRTR)

Research contract, Ramón y Cajal programme.

LR: Dr. Natàlia Vilor-Tejedor

Funding: AEI – Ministry of Science, Innovation and Universities

Reference: Project RYC2022-038136-I funded by AEI and co-financed by the European Union (FSE+)



The role of pregnancy history in women at risk for Alzheimer's disease.

LR: Dr. Anna Brugulat-Serrat

Funding: Alzheimer's Association

Reference: Project AACSF-23-1145154 funded by the Alzheimer's Association

Interplay between subclinical atherosclerosis and Alzheimer's disease in midlife.

LR: Dr. Juan Domingo Gispert

Funding: La Marató de TV3

Reference: Project 202318-30-31-32 funded by La Marató de TV3

AD-RIDDLE: Real-world implementation, deployment and validation of early detection tools and lifestyle enhancement.

LR: Dr. Marc Suárez-Calvet

Funding: Innovative Health Initiative Joint Undertaking (IHI), under the powers delegated by the European Commission

Reference: Project 101132933 – AD-RIDDLE funded by IHI and the European Union

PROAD-Prognostic markers of cognitive impairment in people at risk of Alzheimer's disease.

LR: Dr. Marc Suárez-Calvet

Funding: HNA Foundation

Reference: PROAD project financed by the HNA Foundation

Predocdoctoral contract, PFIS.

LR: Felipe Hernández

Funding: Institute of Health Carlos III (ISC III)

Reference: Project FI23/00029 financed by ISCIII and co-financed by the European Union

Research contract, Miguel Servet programme.

LR: Dr. Gonzalo Sánchez-Benavides

Funding: Institute of Health Carlos III (ISC III)

Reference: Project CP23/00039 financed by ISCIII and co-financed by the European Union

The impact of Environmental factors on Aging and Neurodegeneration: Understanding the Links and Implications for Community Health (environmentALment).

LR: Dr. Natàlia Vilor-Tejedor

Funding: Barcelona City Council and "la Caixa" Foundation

Reference: EnvironMENTAL project – 23S06083-001 funded by Barcelona City Council and "la Caixa" Foundation

COMMUTE – Comorbidity mechanisms utilised in healthcare.

LR: Dr. Arcadi Navarro

Funding: The European Health and Digital Executive Agency (HADEA), under the powers delegated by the European Commission

Reference: Project 101136957-COMMUTE funded by HADEA

The William H. Gates, Sr. Fellowship.

LR: Dr. Natàlia Vilor-Tejedor

Funding: Alzheimer's Disease Data Initiative (ADDI)

Reference: William H. Gates Sr. Fellowship, funded by ADDI

Support programmes

Alzheimer's is a disease that affects not only those diagnosed, but also everyone around them. Therefore, in 2023, we have continued our mission to support those caring for family members with Alzheimer's through group support and training programmes, both in-person and online.

The **in-person group therapy programme** has established seven new groups, involving a total of 57 caregivers.

The programme has received a grant awarded by the Department of Social Rights (in charge of the allocation of 0.7% of personal income tax) of the Generalitat de Catalunya and funding from Barcelona City Council, Aigües de Barcelona and Santalucía insurance.

Currently, **1,613 people have participated in the 172 groups** organised since the initiative was launched in 2013 throughout Spain.

The online support programme **"Learn to take care and take care of yourself"** has conducted 33 groups, with 279 participants.

The programme has received a grant from the Department of Health of the Generalitat de Catalunya and also the support of Barcelona City Council, Fundació M. Teresa Rodó, Libra and FIATC.

Since 2021, the year in which the psychoeducational programme began, we have accompanied **483 caregivers in the 57 organised groups**.

1,613

people have participated in the 172 groups

483

caregivers in the 57 organised groups



You make it possible

Collaborators

Patronage Council

Strategic patron



Major patrons



Patrons



Associated companies



Institutional support



Strategic partners



Collaborating entities

Belron Ronnie Lubner Charitable Foundation

RTVE

Caprabo

HC2M BUSINESS

Fundació Naccari Ravà

Fundación Mutualidad Abogacía

Fundació Miquel & Costas

Scientific collaborations

Janssen	IHE. The Swedish Institute for Health Economics
Lilly	Bioartic
Roche Diagnostics	Uniklinik Cologne
Lund University	Figers Brain Health Institute
University of Amsterdam	Maastricht University
Universitat de Barcelona	University of Leicester
Universitat Oberta de Catalunya	Imperial College London
CNIC	Alzheimer Europe
IRSI Caixa	University of Perugia
ViewMind Inc	Davos Alzheimer's Collaborative
Altoida	Fujeribio
KIElements	Sanofi
F. Hoffmann-La Roche Ltd	C2N Diagnostics
University of Gothenburg	Neotiv
IDIBAPS	Fraunhofer-Gesellschaft
Karolinska Institutet	University of Luxembourg
Combinostics	University of Copenhagen
Hospitaux de Bordeaux	Barcelona Supercomputing Center
UKC Ljubljana	University of Vienna
VUMC	Kairntech
University of Eastern Finland	Luxembourg Institute of Health

Unforgettable shops and pharmacies



372 Unforgettable shops



251 Unforgettable pharmacies



See the full list of partners

Members



The solidarity and commitment of our base has not stopped growing during 2023, and this is demonstrated by our figures.


More than **14,000 people** joined our project so that in the future we will all be able to remember, promoting our research and supporting people living with the disease. Thank you for being part of the solution, with your strength we are getting closer to a future without Alzheimer's.

Once again, people and organizations from all over the territory, through unforgettable initiatives and ideas, have put their creativity and perseverance at the service of the fight to defeat this disease.



74,980 Members

Evolution of the number of members



Companies and individuals in solidarity



Lourdes Bullich
Head of Public Affairs and
Communication Condis
Supermarkets

Solidarity rounding for early detection

More and more businesses are joining the **solidarity rounding** initiative. This action not only helps to give visibility to Alzheimer's and obtain funds for research related to the disease, but also helps to promote solidarity and bring the company's values closer to its customers, clients, workers.



From Condis, we wanted to be with some of the entities and foundations that work to improve mental health in our country, including the Pasqual Maragall Foundation. Progress cannot be made without research and without the combined efforts of people, entities, institutions and public and private companies, either. From these lines we encourage everyone to contribute and work for a future without Alzheimer's.



Irene Iborra
Her ice cream shop is an unforgettable shop

Unforgettable shops and pharmacies

In 2023, a total of **372 shops and 251 pharmacies** collaborated with the Pasqual Maragall Foundation so that in the future we can all remember. Bakeries, hairdressers, pharmacies and bars have supported our work in research for the prevention and early detection of Alzheimer's, and have thus become unforgettable shops and pharmacies.



If a person I love started to suffer from Alzheimer's we would select the memories that are most rooted in their history and we would mark them in the memory with aromas, writing and telling the story together with their aroma or their ice cream.

Solidarity initiatives

2023 has been a year in which we haven't stopped doing research, with very hopeful findings that bring us ever closer to a future without Alzheimer's.

And if we have been able to continue with our research, it is thanks to the 523 initiatives carried out by our collaborators, with which together we have managed to raise **€249,212.**



We join forces with the Marina Walk Trail

The solidarity Nordic walk of the Fundació Amics de l'Hospital del Mar and the Pasqual Maragall Foundation raised more than €15,000. This donation has been intended to promote the joint Alzheimer's research project of the Hospital del Mar Institute for Medical Research (IMIM) and the Barcelonaβeta Brain Research Center (BBRC).



Víctor and Laura
unforgettable bride
and groom

Solidarity celebrations

During 2023, more than **200 solidarity celebrations** were organised in favor of our social and scientific project, and thanks to their solidarity they managed to raise **€75,283**.

+200
celebrations



We decided to give our retail budget to a charity and opted for the Foundation in memory of my grandfather, who died of Alzheimer's.



Carmen Martínez
has already made her
solidarity will

Solidarity wills

In 2023, **36 people** announced their solidarity wills and 220 were interested in bequeathing to the next generations a future without Alzheimer's, in which no family has to suffer the consequences of this disease. Thanks to this form of collaboration, the Pasqual Maragall Foundation has contributed **more than €40,000** in 2023.

36
people



I would tell all the people who are thinking of making a charitable legacy that Alzheimer's is a disease, which steals the whole life of those who suffer from it and causes deep suffering in families. I would also tell them that there are currently more than 46 million people affected worldwide, and research alone can prevent this disease from tripling by 2050. And finally, I would ask them: When you no longer need the money, wouldn't you like to help millions of people and families live fully and without this terrible disease?

**pasqual
maragall
foundation**

barcelonaβeta
BRAIN RESEARCH CENTER

pasqual
maragall
foundation

barcelonaβeta
BRAIN RESEARCH CENTER

Can you help us to beat Alzheimer's?

If you are not yet a member,
call **900 545 545** or capture
the QR with your mobile phone.



fpmaragall.org
barcelonabeta.org

Wellington, 30
08005 Barcelona
info@fpmaragall.org
info@barcelonabeta.org

Contact via WhatsApp
620 227 255

